Table 1 Comparison of baseline demographic, clinical and headache characteristics, total MSQ, EF, RP and RR, MIDAS and LDQ, between responders and non-responders at the 24-week visit

Sex

F

41 (80.4)

24 (77.4)

0.7475

M

10 (19.6)

7 (22.58)

Age class (years)

18-34 years

8 (15.7)

5 (16.1)

0.6547

35 - 44 years

20 (39.2)

10 (32.3)

45 - 54 years

18 (35.3)

10 (32.3)

55 - 64 years

5 (9.8)

6 (19.3)

BMI class

(<18) Underweight

2 (4)

1 (3.2)

0.4466

(18–24.9) Normalweight

32 (64)

17 (54.8)

(25–29.9) Overweight

10 (20)

11 (35.5)

(>30) Obese

6 (12)

2 (6.5)

Missing

1

Comorbidity

No

36 (70.6)

25 (80.7)

0.3117

Yes

15 (29.4)

6 (19.3)

Surgery

No

15 (30.6)

7 (23.3)

0.4836

Yes

34 (69.4)

23 (76.7)

Missing

2

1

Headache days/month

15-25

22 (43.1)

17 (54.8)

0.3036

>25

29 (56.9)

14 (45.2)

Headache intensity

Slight

0 (0)

3 (9.7)

0.0639

Moderate

20 (39.2)

9 (29)

Severe

31 (60.8)

19 (61.3)

Headache duration (years)

0 - 10 years

8 (15.7)

3 (9.7)

0.8787

11 - 20 years

12 (23.5)

7 (22.6)

21 - 30 years

16 (31.4)

11 (35.5)

>30 years

15 (29.4)

10 (32.2)

MOH duration (years)

<1 year

7 (13.7)

3 (9.7)

0.6263

1-3 years

13 (25.5)

11 (35.5)

3-5 years

13 (25.5)

5 (16.1)

>5 years

18 (35.3)

12 (38.7)

Over used drugs

Analgesics > 14 days

20 (39.2)

9 (29)

0.3617

Analgesicscombinations > 9 days

5 (9.8)

7 (22.6)

Drugcombinations > 9 days

15 (29.4)

7 (22.6)

Triptancombinations > 9 days

11 (21.6)

8 (25.8)

Median (IQR)

Median (IQR)

p-value

MSQ

40.0 (27.0 - 50.0)

33.0 (24.0 - 41.0)

0.0180

EF

8.0 (4.0 - 12.0)

5.0 (2.0 - 7.0)

0.0330

RP

9.0 (6.0 - 13.0)

6.0 (5.0 - 9.0)

0.0195

RR

23.0 (16.0 - 27.0)

18.0 (15.0 - 24.0)

0.1188

MIDAS

70 (24.0 - 96.0)

38.0 (15.0 - 75.0)

0.1119

LDQ

7.0 (5.0 - 14.0)

8.0 (7.0 - 13.0)

0.5031